Nektar Therapeutics (NKTR)
43.58
-3.41
(-7.26%)
USD |
NASDAQ |
Oct 02, 16:00
43.40
-0.18
(-0.41%)
After-Hours: 20:00
Nektar Therapeutics Net Income (Quarterly) : -40.62M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -40.62M |
| March 31, 2026 | -44.90M |
| December 31, 2025 | -36.08M |
| September 30, 2025 | -35.52M |
| June 30, 2025 | -41.59M |
| March 31, 2025 | -50.88M |
| December 31, 2024 | 7.261M |
| September 30, 2024 | -37.06M |
| June 30, 2024 | -52.36M |
| March 31, 2024 | -36.80M |
| December 31, 2023 | -42.08M |
| September 30, 2023 | -45.84M |
| June 30, 2023 | -51.12M |
| March 31, 2023 | -137.02M |
| December 31, 2022 | -59.69M |
| September 30, 2022 | -59.05M |
| June 30, 2022 | -159.07M |
| March 31, 2022 | -90.39M |
| December 31, 2021 | -145.64M |
| September 30, 2021 | -129.71M |
| June 30, 2021 | -125.52M |
| March 31, 2021 | -122.97M |
| December 31, 2020 | -117.20M |
| September 30, 2020 | -108.59M |
| June 30, 2020 | -80.00M |
| Date | Value |
|---|---|
| March 31, 2020 | -138.65M |
| December 31, 2019 | -112.16M |
| September 30, 2019 | -98.58M |
| June 30, 2019 | -110.29M |
| March 31, 2019 | -119.63M |
| December 31, 2018 | -98.21M |
| September 30, 2018 | -96.14M |
| June 30, 2018 | 971.46M |
| March 31, 2018 | -95.79M |
| December 31, 2017 | -33.83M |
| September 30, 2017 | 60.87M |
| June 30, 2017 | -59.87M |
| March 31, 2017 | -63.87M |
| December 31, 2016 | -42.20M |
| September 30, 2016 | -43.22M |
| June 30, 2016 | -48.60M |
| March 31, 2016 | -19.50M |
| December 31, 2015 | -54.14M |
| September 30, 2015 | -8.203M |
| June 30, 2015 | -52.66M |
| March 31, 2015 | 33.82M |
| December 31, 2014 | -45.68M |
| September 30, 2014 | 70.60M |
| June 30, 2014 | -32.64M |
| March 31, 2014 | -46.20M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Inovio Pharmaceuticals, Inc. | -6.012M |
| Tonix Pharmaceuticals Holding Corp. | -40.55M |
| Capricor Therapeutics, Inc. | -40.73M |
| Kyntra Bio, Inc. | 11.97M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.13M |
| Total Expenses (Quarterly) | 50.75M |
| EPS Diluted (Quarterly) | -1.229 |
| Enterprise Value | 938.97M |
| Gross Profit Margin (Quarterly) | 98.46% |
| Profit Margin (Quarterly) | -401.0% |
| Earnings Yield | -15.37% |
| Normalized Earnings Yield | -14.60 |